Xinlitai announced that the marketing application for sacubatran alisartan amlodipine tablets independently developed by the company has been accepted by the State Drug Administration and is intended to be used to treat essential hypertension. This product is a fixed combination of ARNI and CCB. No similar product has been approved for marketing in the world. If approved, it will enrich the company's high blood pressure product line.

Zhitongcaijing · 2d ago
Xinlitai announced that the marketing application for sacubatran alisartan amlodipine tablets independently developed by the company has been accepted by the State Drug Administration and is intended to be used to treat essential hypertension. This product is a fixed combination of ARNI and CCB. No similar product has been approved for marketing in the world. If approved, it will enrich the company's high blood pressure product line.